

VI. DAFTAR PUSTAKA

- AbuHammad, S. dan Zihlif, M., 2013. Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. *Genomics*, **101**: 213–220.
- Amalina, N.D., Nurhayati, I.P., dan Meiyanto, E., 2017. Doxorubicin Induces Lamellipodia Formation and Cell Migration. *Indonesian Journal of Cancer Chemoprevention*, **8**: 61–67.
- Anonim, 2001¹, Uji Antiinflamasi PGV-0, PGV-1, dan HGV-1 *in vivo*, *Laporan Penelitian*, Bagian Farmakologi Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Anonim, 2001², Toksisitas Akut, Teratogenisitas, dan Ulserogenisitas PGV-0, PGV-1, dan HGV-1 pada Tikus dan Kelinci, *Laporan Penelitian*, Bagian Farmakologi Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Anonim, 2001³, Uji Toksisitas Subkronis PGV-0, PGV-1, dan HGV-1 pada Tikus dan Kelinci, *Laporan Penelitian*, Bagian Farmakologi Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Bailey-Downs, L.C., Thorpe, J.E., Disch, B.C., Bastian, A., Hauser, P.J., Farasyn, T., dkk., 2014. Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression. *PloS one*, **9**: e98624.
- Bandyopadhyay, A., Wang, L., Agyin, J., Tang, Y., Lin, S., Yeh, I.-T., dkk., 2010. Doxorubicin in combination with a small TGF β inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. *PloS one*, **5**: e10365.
- Bibby, M.C., 2004. Orthotopic models of cancer for preclinical drug evaluation. *European Journal of Cancer*, **40**: 852–857.
- Brooks, S.A., Lomax-Browne, H.J., Carter, T.M., Kinch, C.E., dan Hall, D.M., 2010. Molecular interactions in cancer cell metastasis. *Acta histochemica*, **112**: 3–25.
- Carvalho, M.A.P., Costa, E.C., Miguel, S.P., dan Correia, I.J., 2016. Tumor spheroid assembly on hyaluronic acid-based structures: A review. *Carbohydrate polymers*, **150**: 139–148.
- Chabner, B.A. dan Roberts, T.G., 2005. Timeline: Chemotherapy and the war on cancer. *Nature Reviews. Cancer*, **5**: 65–72.
- Chen, G., Chen, Y., Yang, N., Zhu, X., Sun, L., dan Li, G., 2012. Interaction between curcumin and mimetic biomembrane. *Science China Life Sciences*, **55**: 527–532.
- Chircop, M. dan Speidel, D., 2014. Cellular Stress Responses in Cancer and Cancer Therapy. *Frontiers in Oncology*, **4**: .
- Coghlin, C. dan Murray, G.I., 2010. Current and emerging concepts in tumour metastasis. *The Journal of Pathology*, **222**: 1–15.
- Costa, E.C., Moreira, A.F., de Melo-Diogo, D., Gaspar, V.M., Carvalho, M.P., dan Correia, I.J., 2016. 3D tumor spheroids: an overview on the tools and techniques used for their analysis. *Biotechnology Advances*, **34**: 1427–1441.

- Courtneidge, S.A., 2012. *Cell Migration and Invasion in Human Disease: The Tks Adaptor Proteins*. Portland Press Limited.
- Da'i, M. dan Hanwar, D., 2011. Sintesis PGV-0 dengan Katalis Asam dan Pengembangan Analisis Kemurnian dengan HPLC (*High Performance Liquid Chromatography*) 10.
- Da'i, M., Meiyanto, E., Supardjan, A.M., Jenie, U.A., dan Kawaichi, M., 2007. Potensi Antiproliferative Analog Kurkumin Pentagamavunon Terhadap Sel Kanker Payudara T47D. *Artocarpus*, **7**: 14–20.
- Da'i, M., Suhendi, A., Meiyanto, E., Jenie, U.A., dan Kawaichi, M., 2017. Apoptosis induction effect of curcumin and its analogs pentagamavunon-0 and pentagamavunon-1 on cancer cell lines. *Asian Journal of Pharmaceutical and Clinical Research*, **10**: 373.
- de Campos, P.S., Matte, B.F., Diel, L.F., Jesus, L.H., Bernardi, L., Alves, A.M., dkk., 2017. Low Doses of *Curcuma longa* Modulates Cell Migration and Cell-Cell Adhesion: Curcumin impairs cell migration. *Phytotherapy Research*, **31**: 1433–1440.
- Deng, Y., Verron, E., dan Rohanizadeh, R., 2016. Molecular Mechanisms of Anti-metastatic Activity of Curcumin. *Anticancer Research*, **36**: 5639–5648.
- Denisenko, T.V., Pivnyuk, A.D., dan Zhivotovsky, B., 2018. p53-Autophagy-Metastasis Link. *Cancers*, **10**: .
- Dudka, J., Gieroba, R., Korga, A., Burdan, F., Matysiak, W., Jodlowska-Jedrych, B., dkk., 2012. Different Effects of Resveratrol on Dose-Related Doxorubicin-Induced Heart and Liver Toxicity. *Evidence-Based Complementary and Alternative Medicine*, **2012**: 1–10.
- Eccles, S.A., Box, G., Court, W., Sandle, J., dan Dean, C.J., 1994. Preclinical models for the evaluation of targeted therapies of metastatic disease. *Cell Biophysics*, **24–25**: 279–291.
- Elisha, Y., Kalchenko, V., Kuznetsov, Y., dan Geiger, B., 2018. Dual role of E-cadherin in the regulation of invasive collective migration of mammary carcinoma cells. *Scientific Reports*, **8**: .
- Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J., dan Lluch, A., 2012. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. *Cancer Treatment Reviews*, **38**: 698–707.
- Finn, N.A., Findley, H.W., dan Kemp, M.L., 2011. A Switching Mechanism in Doxorubicin Bioactivation Can Be Exploited to Control Doxorubicin Toxicity. *PLoS Computational Biology*, **7**: .
- Galmarini, D., Galmarini, C.M., dan Galmarini, F.C., 2012. Cancer chemotherapy: a critical analysis of its 60 years of history. *Critical Reviews in Oncology/Hematology*, **84**: 181–199.
- Glasauer, A. dan Chandel, N.S., 2014. Targeting antioxidants for cancer therapy. *Biochemical Pharmacology*, **92**: 90–101.
- Gómez-Cuadrado, L., Tracey, N., Ma, R., Qian, B., dan Brunton, V.G., 2017. Mouse models of metastasis: progress and prospects. *Disease Models & Mechanisms*, **10**: 1061–1074.

- Grada, A., Otero-Vinas, M., Prieto-Castrillo, F., Obagi, Z., dan Falanga, V., 2017. Research Techniques Made Simple: Analysis of Collective Cell Migration Using the Wound Healing Assay. *Journal of Investigative Dermatology*, **137**: e11–e16.
- Hamilton, G. dan Rath, B., 2019. Role of circulating tumor cell spheroids in drug resistance. *Cancer Drug Resistance*, .
- Hammadi, N.I., Abba, Y., Hezme, M.N.M., Razak, I.S.A., Kura, A.U., dan Zakaria, Z.A.B., 2017. Evaluation of in vitro efficacy of docetaxel-loaded calcium carbonate aragonite nanoparticles (DTX-CaCO₃NP) on 4T1 mouse breast cancer cell line. *In Vitro Cellular & Developmental Biology - Animal*, **53**: 896–907.
- Hanna, A.D., Lam, A., Tham, S., Dulhunty, A.F., dan Beard, N.A., 2014. Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. *Molecular pharmacology*, **86**: 438–449.
- Hermawan, A., Fitriyani, A., Junedi, S., Ikawati, M., Haryanti, S., Widaryanti, B., dkk., 2011. PGV-0 and PGV-1 Increased Apoptosis Induction of Doxorubicin on MCF-7 Breast Cancer Cells. *Pharmakon*, **12**: 55–59.
- Hernandez-Aya, L.F. dan Gonzalez-Angulo, A.M., 2013. Adjuvant systemic therapies in breast cancer. *The Surgical Clinics of North America*, **93**: 473–491.
- Hoffman, R.M., 1999. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. *Investigational new drugs*, **17**: 343–360.
- Hu, C., Li, M., Guo, T., Wang, S., Huang, W., Yang, K., dkk., 2019. Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT. *Phytomedicine*, **58**: 152740.
- Hu, X. dan Beeton, C., 2010. Detection of functional matrix metalloproteinases by zymography. *JoVE (Journal of Visualized Experiments)*, e2445.
- Ikawati, M. dan Septisetyani, E.P., 2018. Pentagamavunone-0 (PGV-0), a Curcumin Analog, Enhances Cytotoxicity of 5-Fluorouracil and Modulates Cell Cycle in WiDr Colon Cancer Cells. *Indonesian Journal of Cancer Chemoprevention*, **9**: 23.
- Kaur, P., Nagaraja, G.M., Zheng, H., Gizachew, D., Galukande, M., Krishnan, S., dkk., 2012. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. *BMC cancer*, **12**: 120.
- Kleiner Jr, D.E. dan Stetler-Stevenson, W.G., 1993. Structural biochemistry and activation of matrix metalloproteinases. *Current opinion in cell biology*, **5**: 891–897.
- Koch, A., Tamez, P., Pezzuto, J., dan Soejarto, D., 2005. Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. *Journal of Ethnopharmacology*, **101**: 95–99.
- Kusumastuti, R., Utomo, R.Y., Khumaira, A., Putri, H., Jenie, R.I., dan Meiyanto, E., 2019. Pentagamaboronon-0 increased cytotoxicity of and inhibited metastasis induction by doxorubicin in breast cancer cells. *Journal of Applied Pharmaceutical Science*, **9**: 043–051.

- Larasati, Y.A., Yoneda-Kato, N., Nakamae, I., Yokoyama, T., Meiyanto, E., dan Kato, J., 2018. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. *Scientific Reports*, **8**: 1–13.
- Lee, A. dan Djamgoz, M.B.A., 2018. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. *Cancer Treatment Reviews*, **62**: 110–122.
- Lovitt, C.J., Shelper, T.B., dan Avery, V.M., 2018. Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. *BMC Cancer*, **18**: .
- Mantovani, F., Collavin, L., dan Del Sal, G., 2019. Mutant p53 as a guardian of the cancer cell. *Cell Death & Differentiation*, **26**: 199–212.
- Meiyanto, E., Margono, S.A., dan Da'i, M., 2003. Antiproliferative effect of PGV-0 (a curcumin analogue) against HeLa cells. *Gama Sains*, **5**: 200–206.
- Meiyanto, E., Putri, D.D.P., Susidarti, R.A., Murwanti, R., Sardjiman, S., Fitriasari, A., dkk., 2014a. Curcumin and its Analogues (PGV-0 and PGV-1) Enhance Sensitivity of Resistant MCF-7 Cells to Doxorubicin through Inhibition of HER2 and NF-kB Activation. *Asian Pacific Journal of Cancer Prevention*, **15**: 179–184.
- Meiyanto, E., Putri, D.D.P., Susidarti, R.A., Murwanti, R., Sardjiman, S., Fitriasari, A., dkk., 2014b. Curcumin and its Analogues (PGV-0 and PGV-1) Enhance Sensitivity of Resistant MCF-7 Cells to Doxorubicin through Inhibition of HER2 and NF-kB Activation. *Asian Pacific Journal of Cancer Prevention*, **15**: 179–184.
- Meiyanto, E., Putri, H., Larasati, Y.A., Utomo, R.Y., Jenie, R.I., Ikawati, M., dkk., 2019. Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation.
- Miller, F.R., Miller, B.E., dan Heppner, G.H., 1983. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. *Invasion & metastasis*, **3**: 22–31.
- Mock, C.D., Jordan, B.C., dan Selvam, C., 2015. Recent advances of curcumin and its analogues in breast cancer prevention and treatment. *RSC Advances*, **5**: 75575–75588.
- Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *Journal of Immunological Methods*, **65**: 55–63.
- Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., Janssens, S., Crijns, H.J., dan Moens, A.L., 2012. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. *Journal of Molecular and Cellular Cardiology*, **52**: 1213–1225.
- Perou, C.M., 2011. Molecular stratification of triple-negative breast cancers. *The oncologist*, **16**: 61–70.
- Pulaski, B.A. dan Ostrand-Rosenberg, S., 2000. Mouse 4T1 breast tumor model. *Current protocols in immunology*, **39**: 20–2.

- Putri, H., Jenie, R.I., Handayani, S., Kastian, R.F., dan Meiyanto, E., 2016. Combination of Potassium Pentagamavunon-0 and Doxorubicin Induces Apoptosis and Cell Cycle Arrest and Inhibits Metastasis in Breast Cancer Cells. *Asian Pac. J. Cancer Prev*, **17**: 2683–2688.
- Reddy, K.B., Krueger, J.S., Kondapaka, S.B., dan Diglio, C.A., 1999. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. *International Journal of Cancer*, **82**: 268–273.
- Ren, Z., Chen, J., dan Khalil, R.A., 2017. Zymography as a research tool in the study of matrix metalloproteinase inhibitors, dalam: *Zymography*. Springer, hal. 79–102.
- Robinson, T.P., Ehlers, T., Hubbard Iv, R.B., Bai, X., Arbiser, J.L., Goldsmith, D.J., dkk., 2003. Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. *Bioorganic & medicinal chemistry letters*, **13**: 115–117.
- Rötzer, V., Hartlieb, E., Winkler, J., Walter, E., Schlipp, A., Sardy, M., dkk., 2016. Desmoglein 3-Dependent Signaling Regulates Keratinocyte Migration and Wound Healing. *Journal of Investigative Dermatology*, **136**: 301–310.
- Sant, S. dan Johnston, P.A., 2017. The production of 3D tumor spheroids for cancer drug discovery. *Drug Discovery Today: Technologies*, **23**: 27–36.
- Sardjiman, S.S., Reksohadiprodjo, M.S., Hakim, L., Van der Goot, H., dan Timmerman, H., 1997. 1, 5-Diphenyl-1, 4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. *European Journal of Medicinal Chemistry*, **32**: 625–630.
- Septisetyani, E.P., Ikawati, M., Widaryanti, B., dan Meiyanto, E., 2008. 'Apoptosis Mediated Cytotoxicity of Curcumin Analogues PGV-0 and PGV-1 in WiDr Cell Line', , dalam: *Proceeding Molecular Targeted Therapy Symposium. Faculty of Pharmacy, Gadjah Mada University, Yogyakarta*. hal. 48–56.
- Seyfoori, A., Samiei, E., Jalili, N., Godau, B., Rahmanian, M., Farahmand, L., dkk., 2018. Self-filling microwell arrays (SFMA) for tumor spheroid formation. *Lab on a Chip*, **18**: 3516–3528.
- Shah, M.A. dan Schwartz, G.K., 2001. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. *Clinical cancer research*, **7**: 2168–2181.
- Sodek, K.L., Ringuette, M.J., dan Brown, T.J., 2009. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. *International Journal of Cancer*, **124**: 2060–2070.
- Sullu, Y., Demirag, G.G., Yildirim, A., Karagoz, F., dan Kandemir, B., 2011. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. *Pathology - Research and Practice*, **207**: 747–753.
- Sutejo, I.R., Putri, H., Meiyanto, E., dan Kalimantan, J., 2016. Selektivitas Ekstrak Etanolik Buah Makassar (*Brucea javanica*) pada Kanker Payudara Metastasis secara In Vitro **2**: 5.
- Tao, K., Fang, M., Alroy, J., dan Sahagian, G.G., 2008. Imagable 4T1 model for the study of late stage breast cancer. *BMC cancer*, **8**: 228.

- van Zijl, F., Krupitza, G., dan Mikulits, W., 2011. Initial steps of metastasis: Cell invasion and endothelial transmigration. *Mutation Research*, **728**: 23–34.
- Wang, N., Tang, Z.M., Zhang, Y.P., dan Ding, Q.M., 1996. Doxorubicin cellular pharmacokinetics plays no role in chemosensitizing effect of verapamil on Swiss-3T3 cells. *Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica*, **17**: 402–406.
- Wondrak, G.T., 2014. *Stress Response Pathways in Cancer: From Molecular Targets to Novel Therapeutics*. Springer, New York.
- Yang, J., Guo, W., Wang, L., Yu, L., Mei, H., Fang, S., dkk., 2017. Notch signaling is important for epithelial-mesenchymal transition induced by low concentrations of doxorubicin in osteosarcoma cell lines. *Oncology letters*, **13**: 2260–2268.
- Yerlikaya, A. dan Erin, N., 2008. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. *International journal of molecular medicine*, **22**: 817–823.
- Yerlikaya, A., Okur, E., dan Ulukaya, E., 2012. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. *Tumor Biology*, **33**: 1385–1392.
- Yuwono, T. dan Oetari, R.A., 2005. The stability of PGV-0 (Pentagamavunon-0) as an Antiinflammatory drug in liquid dosage forms. *INDONESIAN JOURNAL OF PHARMACY*, 20–25.
- Zanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., dkk., 2016. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. *Scientific reports*, **6**: 19103.